Silence Therapeutics plc (SLN)
| Previous Close | 21.88 |
| Open | 21.75 |
| Bid | 21.70 x 100 |
| Ask | 22.44 x 100 |
| Day's Range | 21.70 - 22.20 |
| 52 Week Range | 4.84 - 27.72 |
| Volume | |
| Avg. Volume | 239,841 |
| Market Cap | 1.127B |
| Beta (5Y Monthly) | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 57.47 |
Business WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
LONDON, April 30, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20th at 2:30 p.m. ET.
Business WireSilence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
LONDON, April 29, 2024--Silence Therapeutics plc (Nasdaq: SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.
ZacksSilence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
